Correlation of Microsatellit Instability with Morphological Findings in Endometrial Carcinomas
Abstract
Objectives: To understand the prognosis of endometrial carcinomas and determine their treatment, it is becoming increasingly important to
evaluate microsatellite instability (MSI) in endometrial carcinomas and to understand the molecular profile of the tumors. So, in our study, we
aimed to determine morphological parameters in patients whose MSI status was investigated immunohistochemically and molecularly in the last
two years.
Materials and Methods: Forty-three patients with endometrial carcinoma, whose microsatellite stability was investigated, were included in the
study. Patient age, tumor size and tumor localization, type of material sent and resection material, TNM stage, immunohistochemical staining
results and sequencing analysis results, if performed, were obtained from pathology reports and recorded. The H&E stained glasses of the patients
were removed from the archive and reevaluated retrospectively. The presence of intratumoral and peritumoral inflammatory cell infiltration,
lymphovascular and perineural invasion were examined and recorded.
Results: Peritumoral and intratumoral inflammatory cell response was found to be mild (+1) in all MSS cases. In the MSI group, the peritumoral
inflammatory response was mild (+1) in 5 (28%) tumors, moderate (+2) in 11 (61%) tumors, and severe (+3) in 2 (11%) tumors. Intratumoral
inflammation was mild (+1) in 3 (17%) tumors, moderate (+2) in 8 (44%) tumors, and severe (+3) in 7 (39%) tumors. There was a statistically
significant difference between the two groups in terms of both peritumoral and intratumoral inflammation (p<0.05 and p<0.001).
Conclusion: In the MSI group, both intratumoral and peritumoral inflammatory cell densities were found to be higher than in the MSS group,
similar to the literature (p<0.001 and p<0.05, respectively). Many studies in the literature have shown that d-MMR or MSI-H group tumors respond
much better to PD-1 inhibition treatments. This creates a treatment choice for this group of tumors, which are known to have a worse prognosis
than MSS and d-MMR group tumors.
Keywords
References
- 1. Bell DW, Ellenson LH. Molecular Genetics of Endometrial Carcinoma. Annu Rev Pathol. 2019;14:339-367.
- 2. Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome. Int J Cancer. 2022;150:7-17.
- 3. Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behaviour of tumours. J Cancer Res Clin Oncol. 2019;145:2891-2899.
- 4. Olave MC, Graham RP. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosomes Cancer. 2022;61:314-321.
- 5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10-17.
- 6. Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020;76:52-63.
- 7. Stinton C, Fraser H, Al-Khudairy L, et al. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy. Gynecol Oncol. 2021;160:148-160.
- 8. Hussein YR, Soslow RA. Molecular insights into the classification of highgrade endometrial carcinoma. Pathology. 2018;50:151-161.
- 9. Wadee R, Grayson W. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome. Ann Diagn Pathol. 2019;39:92-104.
- 10. Kurnit KC, Westin SN, Coleman RL. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019;125:2154-2163.